# Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma

> **NCT05287945** · PHASE1,PHASE2 · RECRUITING · sponsor: **Oncorena AB** · enrollment: 75 (estimated)

## Conditions studied

- Carcinoma, Renal Cell

## Interventions

- **DRUG:** Orellanine

## Key facts

- **NCT ID:** NCT05287945
- **Lead sponsor:** Oncorena AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-04
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05287945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05287945, "Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05287945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*